An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score

[1]  S. Johnston,et al.  Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. , 2013, Seminars in arthritis and rheumatism.

[2]  Mary K. Kowal,et al.  Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. , 2013, The American journal of medicine.

[3]  O. Baser,et al.  Derivation of severity index for rheumatoid arthritis and its association with healthcare outcomes , 2012, Journal of medical economics.

[4]  S. Schneeweiss,et al.  Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. , 2011, JAMA.

[5]  C. Spettell,et al.  The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents , 2011, Annals of the rheumatic diseases.

[6]  S. Schneeweiss,et al.  Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis , 2010, Arthritis research & therapy.

[7]  Y. Goekoop-Ruiterman,et al.  DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[8]  M. Dougados,et al.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate , 2008, Annals of the rheumatic diseases.

[9]  Jeffrey N Katz,et al.  Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study , 2008, Arthritis research & therapy.

[10]  T. Pincus.  A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. , 2007, Bulletin of the NYU hospital for joint diseases.

[11]  M Alan Brookhart,et al.  Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. , 2006, Arthritis and rheumatism.

[12]  F. Wolfe,et al.  Can severity be predicted by treatment variables in rheumatoid arthritis administrative data bases? , 2006, The Journal of rheumatology.

[13]  M. Hudson,et al.  Antirheumatic drug use and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[14]  D. M. van der Heijde,et al.  The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 , 2006, Arthritis research & therapy.

[15]  J. Avorn,et al.  The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 , 2006, Arthritis research & therapy.